Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.
An anti-infective immunotherapy developer on a mission to replace antibiotics with engineered antibodies and novel mechanisms.
In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.
Board Chairman & CEO Gabriel Baertschi talks about why the private, European-based company is widening its base with new approaches and technologies for treating pain and, now, related conditions.
At BIO CEO many of the companies on my radar this year are in the metabolic/endocrinology area, over which diabetes has long reigned. But the area is now expanding noticeably into other spheres such as neurodegeneration and cardiovascular. As Albion Fitzgerald, chairman of CohBar, says “During the next 15 years, there will be five times as many deaths from noncommunicable diseases as from the old historic communicable diseases, and most noncommunicable diseases are metabolic diseases.”
There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.
Why shouldn’t our mitochondria want us to live long, prospering in good health? Why shouldn’t they — as symbiotic microbes turned cellular organelles with their own mini-genomes — carry genes that help ensure our healthful survival?
At the JPM conference, I spend the bulk of my time meeting with a string of companies, but as various as they are, they all share the common challenge of risk and uncertainty in the development of human therapeutics. For us in the press, it can be tempting to toss companies into easy categories such as size, stage of research, market cap - but then, it’s fun and interesting to let the patterns among the companies emerge spontaneously as each one falls into context. The following describes just a couple of examples.
On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance
In this exclusive with Sue Dillon, Ph.D., head of Janssen Immunology, she talks candidly about topics such as how the company marries the precommercial and commercial functions.
Because I live only a day-trip away from San Francisco, it is convenient for me to travel there for industry events — a trek always accompanied by reflective reveries for the hometown of my film-student days. So, for the third time since June, and with another week scheduled for early January, I am once again city-bound, leaving home mid-day and getting into my hotel in plenty of time to make the 5:30 PM reception for the annual Pantheon Awards dinner, held by the California Life Science Association (CLSA).
We posed some difficult questions to biopharma-company leaders on tough political, economic, and business challenges — those likely to become even tougher for the industry in 2017. The bravest among the invited answered our queries with thoughtful responses regarding thorny issues such as Brexit and the U.S. election, drug pricing and reimbursement, new life science business models, and the industry’s technological future.
This year, the BIO Investor Forum (#BIF16) in San Francisco enjoyed its largest turnout ever, basked in the light and warmth of a dynamic industry that may not solve all of the world’s problems, but shines upon us, a salubrious star. Will the industry’s star shine upon everyone, or leave most of humanity in the shadows?
There is an obvious, timely issue with Catabasis that deserves observation but should not eclipse the whole of the company — its Phase 2 candidate for treating DMD.